Polaryx Therapeutics, Inc.
PLYX Nasdaq Pharmaceutical Preparations Financials FY2024–FY2025
Last close · Oct 23, 2026
$1.85
4.6%What Polaryx Therapeutics, Inc. does
No business description yet.
- Legal name
- Polaryx Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Accession · CIK
- 0001213900-26-033064
0002075320
Revenue and margins
Polaryx Therapeutics, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Polaryx Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 32.8%.
Balance sheet
Cash, debt and the ratios that show how comfortably Polaryx Therapeutics, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $4.6M | $5.1M |
| Current ratio | 17.3x | 8.5x |
| Quick ratio | 17.3x | 8.5x |
| Total assets | $5.0M | $5.2M |
| Total liabilities | $0.3M | $0.6M |
| Shareholders' equity | $4.7M | $4.6M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✕ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — / 3 | — / 6 |
| Accruals ratio | −555.5% | −99.1% |
| Altman Z'' | −41.64 | −59.28 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Research and development | $2.8M | $6.3M |
| Operating income | −$4.4M | −$7.8M |
| Pretax income | −$30.4M | −$9.0M |
| Net income | −$30.4M | −$9.0M |
| Diluted EPS | −$0.89 | −$0.20 |
| Diluted shares | 0.03B | 0.05B |
| Cash flow | ||
| Cash from operations | −$2.6M | −$3.9M |
| Stock-based compensation | $2.4M | $4.7M |
| Balance sheet | ||
| Cash and short-term investments | $4.6M | $5.1M |
| Current assets | $5.0M | $5.2M |
| Current liabilities | $0.3M | $0.6M |
| Total assets | $5.0M | $5.2M |
| Total liabilities | $0.3M | $0.6M |
| Shareholders' equity | $4.7M | $4.6M |
| Returns | ||
| Return on capital employed | −92.4% | −171.3% |
| Return on equity | −644.2% | −193.7% |
| Return on assets | −607.0% | −176.7% |
| Return on tangible equity | −644.2% | −196.8% |
| Growth | ||
| Share count change | — | 32.8% |
| Financial health | ||
| Current ratio | 17.3x | 8.5x |
| Quick ratio | 17.3x | 8.5x |
| Quality scores | ||
| Altman Z'' | −41.6 | −59.3 |
| Accruals ratio | −555.5% | −99.1% |
Source: SEC EDGAR XBRL filings (CIK 0002075320). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.